

Production

We recognize that the establishment of a stable supply of generic drugs is a social responsibility of a generics manufacturer. As the industry leader, we are leading the way in undertaking reinforcement of production and supply systems.

With stable supply as the watchword, Sawai is upgrading its production system.

With stable supply as our watchword, Sawai has actively engaged in forward-looking investment to upgrade production capacity and achieved the highest level in the generic drugs industry. We have earned the trust of wholesale distributors and medical institutions, alike, thanks to a solid track record in stable supply made possible by this production capability.









We will increase annual production capacity from approximately 5.6 billion tablets at present to 6.0 billion tablets during fiscal 2011 by making capital investments at the Company's Sanda Factory in Hyogo Prefecture and other factories and establishing efficient production and supply systems. Furthermore, in preparation for future demand expansion, we have commenced construction of a new plant on the grounds of the Kanto Factory in Mobarra City, Chiba Prefecture and will increase annual production capacity to 8.0 billion tablets by the end of fiscal 2012. The plan is to establish management standards that com-

ply with regulations in Japan, the U.S. and Europe and equip the plant with state-of-the-art facilities that will make possible laborsaving and unattended production and ensure low environmental impact.


Sawai has the industry's top product line and emphasizes new products. In addition to establishing a high-variety, low-volume production system, a characteristic requirement of the generic drugs business, we will expand production lines for products for DPC hospitals, including prefilled syringes and injection solutions.

We believe that above all, the most important task for a generics company is to secure high quality and stable supply by preparing and implementing an appropriate production plan. Accordingly, we will work to further boost production efficiency at our factories and establish production and supply systems aligned with market needs.

Major Factories of Sawai Pharmaceutical

	Factory Outline	Special Features	Production Capacity
Kyushu Factory (Fukuoka Prefecture) 	Site Area: 70,351m ² Total Floor Area: 22,277m ² Production Capacity: 830 million tablets, 36 million V/A/PFS Dosage Forms Handled: Injection, granules, capsules, tablets, ointments	<ul style="list-style-type: none"> The main plant and the historical center of the Sawai Pharmaceutical Group Handles a broad spectrum of dosage forms Includes production facilities for injection solutions 	
Sanda Factory (Hyogo Prefecture) 	Site Area: 14,686m ² Total Floor Area: 21,932m ² Production Capacity: 2,600 million tablets Dosage Forms Handled: Tablets	<ul style="list-style-type: none"> Dedicated tablet factory Completed third-stage expansion in 2009, increasing production capacity 1.5 times, 5.3 billion tablet production system established. Features production facilities for special drugs like hormone solutions. 	
Kanto Factory (Chiba Prefecture) 	Site Area: 85,046m ² Total Floor Area: 7,740m ² Production Capacity: 543 million tablets, 2 million V/A/PFS Dosage Forms Handled: Tablets, capsules, granules, injection, other	<ul style="list-style-type: none"> Includes Sawai's own syringe plant, a rarity among drug manufacturers 	
Kyushu Factory of Medisa Shinyaku (Fukuoka Prefecture) 	Site Area: 34,103m ² Total Floor Area: 16,300m ² Production Capacity: 1,600 million tablets Dosage Forms Handled: Tablets, granules, other	<ul style="list-style-type: none"> Construction work for sixth-stage expansion finished in 2008 Largest factory among our group companies, with large facilities for special drugs like OD tablets 	

Company's Production Capacity



Production Facilities

